Vertex Pharmaceuticals has seen a 12% revenue uptick in Q3 compared to the same period in 2023 as it prepares launches for two new separate therapies in cystic fibrosis and pain.
Reporting on its Q3 financials this year, Vertex said its full-year product revenue rose from $10.65bn-$10.85bn to $10.8bn-$10.9bn.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe 12% revenue increase has notched sales up to $2.77bn, as per a 4 November press release.
Shares in the US company closed 0.35% higher on 4 November compared to the previous close pre-announcement. Shares rose again by 2.11% at market open on 5 November compared to the previous market close. Vertex has a market cap of $122bn.
Vertex’s lead cystic fibrosis treatment Trikafta (elexacaftor / tezacaftor / ivacaftor) was once again the primary driver behind the drugmaker’s positive financial performance. The triple-combination therapy generated nearly $2.6bn in Q3 sales, compared to $2.27bn made in the same period last year.
The pharma company could soon be bolstering its cystic fibrosis portfolio in the form of a once-daily vanzacaftor triple therapy (vanzacaftor / tezacaftor / deutivacaftor). The treatment has a Prescription Drug User Fee Act (PDUFA) target action date of January 2025 in the US, with the US Food and Drug Administration (FDA) also granting it priority review. Vertex added it has also completed regulatory submissions for the vanzacaftor triple therapy in the EU, UK, and Canada, among others.
In development is an mRNA therapy for cystic fibrosis, with Vertex stating it has completed a single ascending dose (SAD) portion of a Phase I/II study evaluating the candidate named VX-522.
Vertex also has another PDUFA in January 2025 as the vanzacaftor triple therapy, with the FDA set to review suzetrigine for the treatment of moderate-to-severe pain. Suzetrigine is estimated to reach blockbuster status by 2029 and achieve $1.4bn in sales by 2030, according to an analysis by GlobalData’s Pharma Intelligence Centre.
GlobalData is the parent company of Pharmaceutical Technology.
Vertex also issued an update for its cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) cell therapy Casgevy (exagamglogene autotemcel). The company has now activated 45 treatment centres around the world for the therapy, which had its revenue from the first infused patient included in the Q3 financials. In August, the UK’s NHS rolled out the treatment following a positive recommendation by the National Institute for Health and Care Excellence (NICE), which Vertex said impacted the guidance change.
Also notching up the guidance was Vertex’s acquisition of Alpine Immune Sciences earlier this year, a deal that saw the drugmaker spend $4.9bn to bolster its immunotherapy pipeline.
Vertex CEO Reshma Kewalramani said: “The third quarter marked another period of strong progress […] and we are again increasing our full-year product revenue guidance. Launch preparedness is well underway as we look forward to the potential approvals of the vanzacaftor triple for cystic fibrosis and suzetrigine.”
